繁體
  • 简体中文
  • 繁體中文

熱門資訊> 正文

CRISPR Therapeutics股价因3.5亿美元可转换债券发行而下跌

2026-03-10 19:07

  • CRISPR Therapeutics (CRSP) plans to offer $350M aggregate principal amount of its convertible senior notes due 2031 in a private offering.
  • The company also expects to grant the initial purchasers a 13-day option to purchase up to an additional $52.5M aggregate principal amount of the notes.
  • The notes will accrue interest payable semiannually and will mature on March 1, 2031, unless earlier converted, redeemed, or repurchased.
  • The biopharmaceutical company plans to use the net proceeds from the offering for general corporate purposes.
  • CRSP shares fell -6.5% premarket to $54.94.

風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。